Inspection prep notes · Supply, manufacturing and packaging
Contract testing and quality agreements
Also called: contract testing laboratory, contract laboratory, quality agreement
FDA looks less at whether work was contracted out than at who is responsible for that work and how it is checked. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1No quality agreement was in place
You do not have a written procedure or a quality agreement describing the roles and responsibilities between you, as the contract manufacturing organization, and your customer regarding testing requirements and established product specifications.
FDA Warning Letter · TCI Co., Ltd BioCosme PABP BRANCH · 2026-10-06 · View document
Specifically, there is no quality agreement established with [redacted] regarding mycoplasma release testing.
FDA 483 · Clongen Laboratories, LLC · 2026-10-30 · View document
2The contract testing laboratory was not qualified
You did not qualify your active pharmaceutical ingredients (API) supplier, and your contract testing laboratory used for API testing.
FDA Warning Letter · Outin Futures Corp. · 2024-10-15 · View document
In addition, during the inspection you acknowledged that your QU did not qualify the contract laboratories you used to support product release due to resource issues.
FDA Warning Letter · Fagron Group B.V. · 2022-06-28
3The method used by the contract laboratory was not verified
For example, your firm failed to verify the residual solvent method used by your contract testing laboratory.
FDA Warning Letter · Shimoga Chemicals · 2026-07-21 · View document
Your firm did not have documentation of a method validation or method verification performed by the contract laboratory of its modified version equivalency to USP <61> and USP <62>.
FDA 483 · Enemeez LLC · 2026-07-13 · View document
4Testing at the contract laboratory was not overseen
Your quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted.
FDA Warning Letter · Advanced Pharmaceutical Technology · 2025-03-18 · View document
Specifically, There is a failure to thoroughly review any unexplained discrepancy from the firm's contract testing lab used for stability studies of ERVEBO drug product vaccine and related materials.
FDA 483 · Burgwedel Biotech GmbH · 2026-10-26
5After problems at the contract laboratory, it was not audited and its corrective actions were not checked
The QCU did not audit the contract testing laboratory during the period in which 13 OOS results were generated.
FDA 483 · Brookfield Medical Surgical Supplies Inc · 2026-09-10 · View document
No investigation was performed as to whether appropriate corrective actions were taken by the contract lab to prevent the problem from reoccurring.
FDA 483 · Duke University · 2026-10-30 · View document
Questions to check against your procedures
- Is there a quality agreement with each contract manufacturer, contract laboratory and customer?
- Does the quality agreement state the roles and responsibilities for testing requirements and product specifications?
- Was the contract testing laboratory qualified before it was used?
- Do you hold method validation or verification documentation for the methods the contract laboratory uses?
- Does the quality unit review discrepancies and deviations from the contract laboratory?
- After OOS results or errors at the contract laboratory, was the laboratory audited and were its corrective actions checked?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.